SEC Comment Letter 0000000000-23-000148 to Emergent Health Corp. (EMGE) (CIK 0001463459)

Emergent Health Corp. (EMGE) (CIK 0001463459)
Date: Jan. 5, 2023 · CIK: 0001463459 · Accession: 0000000000-23-000148

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 024-11708

Date

January 5, 2023

Author

cc: Eric Newlan

Form

UPLOAD

Company

Emergent Health Corp. (EMGE) (CIK 0001463459)

Letter

United States securities and exchange commission logo January 5, 2023 James Morrison Chief Executive Officer Emergent Health Corp. 50 Motor Parkway, Suite 401 Hauppauge, New York 11787 Re:Emergent Health Corp. Offering Statement on Form 1-A Post-qualification Amendment No. 2 Filed January 3, 2023 File No. 024-11708 Dear James Morrison: This is to advise you that we do not intend to review your amendment. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jennie Beysolow at 202-551-8108 with any questions.

Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc: Eric Newlan

Show Raw Text

United States securities and exchange commission logo
January 5, 2023
James Morrison
Chief Executive Officer
Emergent Health Corp.
50 Motor Parkway, Suite 401
Hauppauge, New York 11787
Re:Emergent Health Corp.
Offering Statement on Form 1-A
Post-qualification Amendment No. 2
Filed January 3, 2023
File No. 024-11708
Dear James Morrison:
            This is to advise you that we do not intend to review your amendment.
            We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Please contact Jennie Beysolow at 202-551-8108 with any questions.

Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc:       Eric Newlan

SecProbe.io